- Home
- MRNA vs CLS Comparison
MRNA vs CLS Comparison
Compare MRNA & CLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- CLS
- Stock Information
- Founded
- MRNA 2010
- CLS 1994
- Country
- MRNA United States
- CLS Canada
- Employees
- MRNA N/A
- CLS N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- CLS Electrical Products
- Sector
- MRNA Health Care
- CLS Technology
- Exchange
- MRNA Nasdaq
- CLS Nasdaq
- Market Cap
- MRNA 10.9B
- CLS 9.7B
- IPO Year
- MRNA 2018
- CLS 1998
- Fundamental
- Price
- MRNA $25.87
- CLS $248.44
- Analyst Decision
- MRNA Hold
- CLS Strong Buy
- Analyst Count
- MRNA 19
- CLS 10
- Target Price
- MRNA $43.50
- CLS $190.70
- AVG Volume (30 Days)
- MRNA 12.2M
- CLS 3.2M
- Earning Date
- MRNA 11-06-2025
- CLS 10-27-2025
- Dividend Yield
- MRNA N/A
- CLS N/A
- EPS Growth
- MRNA N/A
- CLS 55.91
- EPS
- MRNA N/A
- CLS 4.59
- Revenue
- MRNA $3,078,000,000.00
- CLS $10,587,200,000.00
- Revenue This Year
- MRNA N/A
- CLS $20.66
- Revenue Next Year
- MRNA $10.17
- CLS $17.22
- P/E Ratio
- MRNA N/A
- CLS $53.99
- Revenue Growth
- MRNA N/A
- CLS 20.52
- 52 Week Low
- MRNA $23.15
- CLS $46.14
- 52 Week High
- MRNA $75.37
- CLS $258.16
- Technical
- Relative Strength Index (RSI)
- MRNA 51.44
- CLS 66.17
- Support Level
- MRNA $23.18
- CLS $239.80
- Resistance Level
- MRNA $25.90
- CLS $258.16
- Average True Range (ATR)
- MRNA 1.16
- CLS 12.93
- MACD
- MRNA 0.27
- CLS 1.27
- Stochastic Oscillator
- MRNA 95.05
- CLS 87.21
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About CLS Celestica Inc.
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, The Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity & Cloud Solutions segment.